Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Vorinostat (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 26 Mar 2013 Planned end date changed from 1 Jan 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Planned end date changed from 1 Aug 2007 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top